Partnerships are fundamental to the way in which Novo Nordisk runs its business. They help to build trust among our key stakeholders and to reach a better understanding of a variety of important issues. Partnerships also pave the way for more successful solutions to problems, concerns and challenges. Two examples of global challenges that Novo Nordisk is actively addressing together with key partners are the epidemic growth of type 2 diabetes and climate change.
Access to health
Novo Nordisk co-operates with governments, healthcare providers, NGOs, universities, healthcare professionals and diabetes associations worldwide to establish data, build evidence and pilot new intervention approaches. The new global access programme builds on the experience gained during the past five years of work through several initiatives. Programmes such as the pioneering World Partnership programme in eight developing countries; the pricing policy focused on offering affordable insulin to the world's 49 least developed countries; and the projects funded by the World Diabetes Foundation have one common denominator: they offer a partnership approach to filling gaps in under-resourced and unsustainable healthcare systems.
Read more under our Access to Health section.
WWF Climate Savers initiative
As a member of the World Wide Fund for Nature (WWF) Climate Savers initiative, Novo Nordisk is one of 18 companies that have agreed to work to achieve an absolute reduction in the company's CO2 emissions to combat global warming. Climate Savers is the only programme that helps businesses make and achieve voluntary commitments to reduce the impact of their corporate activities on climate change. WWF works with businesses to develop cost-effective energy strategies to demonstrate that increasing efficiency and aggressively reducing greenhouse gas emissions can benefit the environment and the economy in numerous ways.
Read more about our climate action programme in the Climate Action section.
Establishing a national stem cell research centre
In March 2010 a new Danish national stem cell research centre, DanStem was established at the University of Copenhagen. The centre will comprise two separate sections:
- A section for basic stem cell biology (BasicStem) and
- A section for strategic translational stem cell research and therapy (TransStem).
BasicStem is supported by a grant of 47 million euro from The Novo Nordisk Foundation and TransStem by a grant of 8,7 million euro from the Danish Council of Strategic Research. TransStem researchers will collaborate with the University hospital, Rigshospitalet, Uppsala University and Novo Nordisk A/S.
Read more about our stem cell research.